Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology

被引:86
|
作者
Eikenboom, JCJ [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Haematol, Haemostasis & Thrombosis Res Ctr, NL-2300 RC Leiden, Netherlands
关键词
von Willebrand disease; von Willebrand factor; drug therapy; antibodies; factor VIII; congenital; genetics; mutation;
D O I
10.1053/beha.2001.0139
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease type 3 is the most severe form of this condition. Patients present with a moderate-to-severe bleeding tendency. The plasma von Willebrand factor level in these patients is very low or undetectable. Although rare, von Willebrand disease type 3 is of major interest because of its severe clinical presentation, the need for replacement therapy and the risk of occurrence of alloantibodies after the infusion of plasma concentrates. The inheritance of type 3 disease is typically autosomal recessive. The parents are often consanguineous, although compound heterozygous inheritance does occur. The molecular basis of von Willebrand disease type 3 has recently been studied in detail, several molecular defects being identified. This chapter will focus on the clinical and molecular aspects of type 3 von Willebrand disease.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 50 条
  • [1] Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology
    Mazurier, C
    Goudemand, J
    Hilbert, L
    Caron, C
    Fressinaud, E
    Meyer, D
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) : 337 - 347
  • [2] von Willebrand factor alloantibodies in type 3 von Willebrand disease
    Kotnik, Barbara Faganel
    Strandberg, Karin
    Debeljak, Marusa
    Kitanovski, Lidija
    Jazbec, Janez
    Benedik-Dolnicar, Majda
    Bakija, Alenka Trampus
    BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (01) : 77 - 79
  • [3] The molecular biology of von Willebrand disease
    Ginsburg, D
    HAEMOPHILIA, 1999, 5 : 19 - 27
  • [4] Molecular biology of von Willebrand disease
    Melo-Nava, Brenda
    Penaloza, Rosenda
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2007, 59 (05): : 401 - 408
  • [5] The molecular biology of von Willebrand disease
    Keeney, S
    Cumming, AM
    CLINICAL AND LABORATORY HAEMATOLOGY, 2001, 23 (04): : 209 - 230
  • [6] Von Willebrand disease. Molecular biology and diagnosis
    Hernandez-Zamora, Edgar
    Zavala-Hernandez, Cesar
    Quintana-Gonzalez, Sandra
    Reyes-Maldonado, Elba
    CIRUGIA Y CIRUJANOS, 2015, 83 (03): : 255 - 264
  • [7] Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease
    Lak, M
    Peyvandi, F
    Mannucci, PM
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (04) : 1236 - 1239
  • [8] Molecular characterization of Iranian patients with type 3 von Willebrand disease
    Shahbazi, S.
    Mahdian, R.
    Ala, F. A.
    Lavergne, J. -M.
    Denis, C. V.
    Christophe, O. D.
    HAEMOPHILIA, 2009, 15 (05) : 1058 - 1064
  • [9] Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment
    Rodeghiero, F
    Castaman, G
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) : 321 - 335
  • [10] Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)
    Budde, U.
    Schneppenheim, R.
    Eikenboom, J. .
    Goodeve, A.
    Will, K.
    Drewke, E.
    Castaman, G.
    Rodeghiero, F.
    Federici, A. B.
    Batlle, J. .
    Perez, A.
    Meyer, D.
    Mazurier, C.
    Goudemand, J.
    Ingerslev, J.
    Habart, D.
    Vorlova, Z.
    Holmberg, L.
    Lethagen, S.
    Pasi, J.
    Hill, F.
    Peake, I.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (05) : 762 - 771